Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Rhea-AI Summary

Scinai (Nasdaq: SCNI) announced that CEO Amir Reichman will co-lead a Manufacturers Association roundtable titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" on January 19, 2026 at Expo Tel Aviv during HealthIL Week 2026.

The session will focus on early-stage development, CMC and analytical capabilities, clinical GMP manufacturing, access to laboratory infrastructure, and readiness for later-stage and commercial manufacturing in Israel.

Participants will include government agencies, local and international biopharma companies, CDMOs, multinationals, and investors; the discussion aims to identify structural gaps and collaboration models to strengthen Israel's biopharma manufacturing ecosystem over the next 5–10 years.

Key Figures

Roundtable date January 19, 2026 Biopharma manufacturing roundtable at Expo Tel Aviv

Conference year 2026 HealthIL Week 2026 healthcare innovation conference

Planning horizon 5–10 years Timeframe for evolving national biopharma manufacturing capabilities

Market Reality Check

$0.8053 Last Close

Volume Volume 4,761 is below the 20-day average of 53,626, suggesting limited trading engagement ahead of this event-focused news. low

Technical Shares at $0.8266 are trading below the 200-day MA of $1.82 and remain 86.62% under the 52-week high of $6.18.

Peers on Argus

Peers show mixed moves: SLRX up 25.26%, VRAX up 3.16%, LIPO down 3.91%, indicating today’s action in SCNI is more stock-specific than a broad biotechnology sector rotation.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 02	Nine-month results	Positive	+3.0%	Reported revenue growth and CDMO expansion with updated financial metrics.
Oct 06	Grant funding news	Positive	+1.9%	Non-dilutive IIA grant to expand sterile fill-and-finish CDMO capabilities.
Sep 02	H1 2025 earnings	Positive	+0.7%	H1 results showing CDMO revenue growth and balance sheet strengthening.
Jul 29	Clinical publication	Positive	-2.4%	Peer-reviewed data supporting PC111 as disease-modifying therapy for skin diseases.

Pattern Detected

Recent news and earnings updates have typically led to modest single-digit price moves, with one notable divergence on positive clinical publication news.

Recent Company History

Over the last six months, Scinai has highlighted CDMO growth, grant funding, and pipeline progress. Nine-month 2025 results on Dec 2, 2025 showed higher revenues and CDMO expansion, while six‑month 2025 results on Sep 2, 2025 emphasized revenue growth and a strengthened balance sheet. An Israel Innovation Authority grant on Oct 6, 2025 supported fill‑and‑finish capabilities, and a Jul 29, 2025 publication supported PC111’s potential. Historically, these updates produced modest price reactions within a few percentage points.

Market Pulse Summary

This announcement highlights Scinai’s role in Israel’s biopharma manufacturing ecosystem, with the CEO co‑leading a HealthIL Week 2026 roundtable on capabilities and gaps. It complements prior updates on CDMO expansion and grants that supported sterile fill‑and‑finish capacity. Investors may focus on how participation with government, manufacturers, and CDMOs could translate into future CDMO demand and partnerships, while also monitoring upcoming financial results and any concrete follow‑up from the ecosystem discussions.

Key Terms

cdmo technical

"operating a growing boutique CDMO business unit, today announced that its"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

cmc technical

"focus on early-stage development, CMC activities, and clinical manufacturing across"

Chemistry, Manufacturing, and Controls (CMC) describes the technical documentation and processes that show how a drug or medical product is made, tested for consistent quality, and kept stable from batch to batch. Investors care because strong CMC means a product can be manufactured reliably at scale and meet regulatory standards—similar to proving a recipe can be cooked the same way in any kitchen before restaurants expand—affecting approval, production costs, and potential revenue.

gmp regulatory

"CMC and analytical capabilities, and GMP manufacturing for clinical supply."

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

biologic modalities medical

"global trends shaping biopharma manufacturing, including the increasing complexity of biologic modalities and formats,"

Different types of medical treatments and products made from living material—such as proteins, antibodies, cells, gene therapies and RNA—rather than traditional small-molecule drugs. Investors care because each biologic approach is like a different tool in a toolbox: they have distinct development timelines, manufacturing costs, safety and approval challenges, and competitive barriers, all of which affect a company’s risk profile and potential returns.

AI-generated analysis. Not financial advice.

JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during HealthIL Week 2026.

The roundtable, titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale," will take place on January 19, 2026 at Expo Tel Aviv. The session is a Manufacturers Association–led roundtable and will be jointly led by Mr.  Reichman together with senior representatives of the Manufacturers Association of Israel.

The roundtable was convened at the request of the Manufacturers Association to facilitate a realistic, fact-based discussion on Israel's biopharma development and manufacturing ecosystem, with a particular focus on early-stage development, CMC activities, and clinical manufacturing across the full development continuum.

The discussion will emphasize early-stage development and clinical manufacturing, including access to laboratory infrastructure, CMC and analytical capabilities, and GMP manufacturing for clinical supply. These capabilities form the foundation for efficient development, regulatory readiness, and informed investment decisions.

Within this lifecycle view, the roundtable will examine readiness for later-stage and commercial manufacturing in Israel, the role of local and international CDMOs, and the current scope of manufacturing capabilities, structural gaps, and collaboration models across the ecosystem.

The discussion will further consider global trends shaping biopharma manufacturing, including the increasing complexity of biologic modalities and formats, evolving regulatory expectations, and the growing reliance on specialized CDMOs, and how national capabilities should evolve over the next 5–10 years to remain competitive.

"The Manufacturers Association plays a central role in shaping Israel's industrial capabilities," said Mr.  Reichman. "This roundtable is intended to examine, in a practical and grounded way, whether Israel has the development and manufacturing infrastructure needed to support biopharma companies from early clinical stages onward and what actions are required to strengthen that foundation."

Participants are expected to include representatives from government and public agencies, Israeli and international biopharma manufacturers and CDMOs, multinational pharmaceutical companies, biotech companies with clinical and commercial experience, and investors with direct exposure to biopharma development and manufacturing risk.

HealthIL Week is Israel's leading international conference for healthcare innovation, bringing together stakeholders from industry, academia, government, and the investment community to address challenges shaping the future of healthcare and life sciences.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units:

• Scinai Bioservices, a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide.
• Scinai R&D, focused on developing innovative I&I therapeutics based on NanoAbs (VHH antibody fragments) with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats

Company website: www.scinai.com

Company Contacts

Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter, failure to sign agreements with other potential clients of the CDMO business; failure to receive grants under the EU STEP program or a delay in receiving grant decisions; delay in commencement of commercial operation of advanced sterile fill-and-finish system; a delay in the commencement and results of pre-clinical and clinical studies, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 7, 2025, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scinai-ceo-amir-reichman-to-co-lead-manufacturers-association-biopharma-manufacturing-roundtable-at-healthil-302655108.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What will Scinai CEO Amir Reichman discuss at the HealthIL roundtable on January 19, 2026 (SCNI)?

Mr. Reichman will co-lead a discussion on early-stage development, CMC capabilities, clinical GMP manufacturing, infrastructure gaps, and pathways to commercial readiness.

When and where is the Manufacturers Association biopharma roundtable featuring Scinai (SCNI)?

The roundtable takes place on January 19, 2026 at Expo Tel Aviv during HealthIL Week 2026.

Who is expected to attend the Biopharma Manufacturing in Israel roundtable with Scinai (SCNI)?

Attendees are expected from government and public agencies, Israeli and international biopharma, CDMOs, multinational pharma, biotech companies, and investors.

How will the roundtable chaired by Scinai impact Israel’s biopharma manufacturing capacity (SCNI)?

The session aims to identify structural gaps, collaboration models, and actions to strengthen development and manufacturing infrastructure over the next 5–10 years.

Will the Scinai-led roundtable address CDMO roles and clinical supply challenges (SCNI)?

Yes; the agenda explicitly includes the role of local and international CDMOs and access to GMP manufacturing for clinical supply.

Can investors expect material financial disclosures from Scinai (SCNI) at the HealthIL roundtable?

No financial results or guidance are announced; the session is a sector discussion focused on ecosystem capabilities and policy considerations.